Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation

Sergio Bracarda, Claudia Caserta, Luca Galli, Paolo Carlini, Ilaria Pastina, Michele Sisani, Simona Scali, Alketa Hamzaj, Lisa Derosa, Alessandra Felici, Marta Rossi, Amelia Altavilla, Aldo Chioni, Verena De Angelis

Research output: Contribution to journalArticle

Abstract

Background: We evaluated the possible advantages of a docetaxel (DCT) rechallenge strategy in metastatic castration-resistant prostate cancer (mCRPC) patients, also given the possible earlier positioning of this treatment option in the modern scenario. Patients & methods: All mCRPC patients planned for DCT chemotherapy rechallenge in our institutions were evaluated. Results: Of 128 patients, 98 achieved disease control on the initial DCT round. After a treatment holiday of 8.3 months, the 98 responsive patients underwent a second DCT round, with 56 cases achieving again disease control. After a 5.7-month off-treatment period, 32 of these cases underwent a third DCT round, and 16 responded. Lastly, after a further 4.2-month treatment holiday, eight patients underwent a fourth DCT round and two responded. Median time to definitive disease progression for the whole population was 16.4 months. Conclusions: Rechallenge with DCT may be considered a suitable treatment option for mCRPC patients recurring after a successful DCT chemotherapy. The interest in this strategy may be increased because of the showed efficacy of early DCT chemotherapy in patients with bulky disease (CHAARTED study) and the potential lower efficacy of the new hormonal agents abiraterone acetate and enzalutamide when used in a immediate sequencing.

Original languageEnglish
Pages (from-to)3083-3090
Number of pages8
JournalFuture Oncology
Volume11
Issue number22
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • docetaxel
  • docetaxel rechallenge
  • intermittent chemotherapy
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation'. Together they form a unique fingerprint.

  • Cite this

    Bracarda, S., Caserta, C., Galli, L., Carlini, P., Pastina, I., Sisani, M., Scali, S., Hamzaj, A., Derosa, L., Felici, A., Rossi, M., Altavilla, A., Chioni, A., & De Angelis, V. (2015). Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation. Future Oncology, 11(22), 3083-3090. https://doi.org/10.2217/fon.15.217